Insilico Medicine and SK Biopharmaceuticals have entered an Artificial Intelligence (AI)-powered drug discovery collaboration worth up to USD 2.5 billion to develop innovative therapies for neuroimmune disorders.
Drug Discovery Partnership | 23/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy